New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I - Formulation development and in-vitro characterization

Journal of Controlled Release

Volumn 143, Issue 1, 2010, Pages 143-150

  Tinkov, Steliyan ^a   Winter, Gerhard ^a   Coester, Conrad ^a   Bekeredjian, Raffi ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Contrast agents; Drug targeting; Microbubbles; Tumor therapy; Ultrasound

Indexed keywords

ACTIVE DRUGS; ADVERSE EFFECT; ANTI-PROLIFERATIVE; ANTI-TUMOR EFFICACY; BROAD APPLICATION; CARDIOTOXICITY; CHEMOTHERAPEUTIC DRUGS; CLINICAL TREATMENTS; CONTRAST AGENT; CYTOTOXIC ACTIVITIES; DIAGNOSTIC ULTRASOUND; DOXORUBICIN; DRUG CARRIER; DRUG CONCENTRATION; DRUG LOAD; DRUG-TARGETING; FORMULATION DEVELOPMENT; IN-CELL; IN-VITRO; MICRO-BUBBLE; MICROBUBBLES; PHOSPHOLIPID MONOLAYERS; PHYSICAL CHARACTERISTICS; SOLID TUMORS; TUMOR THERAPY; ULTRASOUND CONTRAST AGENT; ULTRASOUND-TARGETED MICROBUBBLE DESTRUCTION; VASCULATURE;

CELL CULTURE; DRUG PRODUCTS; ELECTRON ENERGY LEVELS; LIPOSOMES; MONOLAYERS; PHOSPHOLIPIDS; TUMORS; ULTRASONIC TRANSMISSION; ULTRASONICS;

DRUG THERAPY;

DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; LIPID MONOLAYER; LIPOSOMAL DELIVERY; MICROBUBBLE; PRIORITY JOURNAL; ULTRASOUND;

ANTIBIOTICS, ANTINEOPLASTIC; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CONTRAST MEDIA; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; HYDROPHOBICITY; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MICROBUBBLES; PARTICLE SIZE; PHOSPHOLIPIDS; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; ULTRASONICS;

EID: 77950521639     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.026     Document Type: Article

References (31)

1. Mayer C., Bekeredjian R. Ultrasonic gene and drug delivery to the cardiovascular system. Adv. Drug Deliv. Rev. 2008, 60(10):1177-1192.
2. Tinkov S., Bekeredjian R., Winter G., Coester C. Microbubbles as ultrasound triggered drug carriers. J. Pharm. Sci. 2009, 98(6):1935-1961.
3. Li P., Armstrong W.F., Miller D.L. Impact of myocardial contrast echocardiography on vascular permeability: comparison of three different contrast agents. Ultrasound Med. Biol. 2004, 30(1):83-91.
4. Song J., Chappell J.C., Qi M., VanGieson E.J., Kaul S., Price R.J. Influence of injection site, microvascular pressure and ultrasound variables on microbubble-mediated delivery of microspheres to muscle. J. Am. Coll. Cardiol. 2002, 39(4):726-731.
5. Lentacker I., Geers B., Demeester J., De Smedt S.C., Sanders N.N. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved. Mol. Ther. 2010, 18(1):101-108.
6. Rapoport N., Gao Z., Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 2007, 99(14):1095-1106.
7. Shortencarier M.J., Dayton P.A., Ferrara K.W., Matsunaga T., LaBell R., Schumann P. Targeted chemotherapy delivery with ultrasound. IEEE Ultrasound Symp. Proc. 2005, 265-268.
8. Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J.M. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim. Biophys. Acta 1980, 597:1-14.
9. Goldman R., Facchinetti T., Bach D., Raz A., Shinitzky M. A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim. Biophys. Acta 1978, 512:254-269.
10. de Wolf F.A. Binding of doxorubicin to cardiolipin as compared to other anionic phospholipids - an evaluation of electrostatic effects. Biosci. Rep. 1991, 11(5):275-284.
11. Rahman A., Ganjei A., Neefe J.R. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother. Pharmacol. 1986, 16:28-34.
12. Rahman A., Joher A., Neefe J.R. Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Br. J. Cancer 1986, 54(3):401-408.
13. Tinkov S., Bekeredjian R., Winter G., Coester C. Characterization of ultrasound-mediated destruction of drug-loaded microbubbles using an improved in-vitro model. Appl. Acoust. 2008, 70(10):1323-1329.
14. European Pharmacopoeia 5.00, Allgemeine Vorschriften, Doxorubicini hydrochloridum. Vol. Grundwerk 5.00, 2005, pp. 2009-2010.
15. Tinkov S. Development of Ultrasound Contrast Agents for Targeted Drug and Gene Delivery 2009, Verlag Dr. Hut, Munich.
16. Elbayoumi T., Torchilin V. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 2007, 32(3):159-168.
17. Wang Z., Pecha R., Gompf B., Eisenmenger W. Single bubble sonoluminescence: investigations of the emitted pressure wave with a fiber optic probe hydrophone. Phys. Rev. E 1999, 59:1777-1780.
18. Apfel R.E., Holland C.K. Gauging the likelihood of cavitation from short-pulse, low-duty cycle diagnostic ultrasound. Ultrasound Med. Biol. 1991, 17(2):179-185.
19. Ward M., Wu J., Chiu J.-F. Experimental study of the effects of optison concentration on sonoporation in vitro. Ultrasound Med. Biol. 2000, 26(7):1169-1175.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65(1-2):55-63.
21. Findlay E.G., Barton P.G. Phase behavior of synthetic phosphatidylglycerols and binary mixtures with phosphatidylcholines in the presence and absence of calcium ions. Biochemistry 1978, 17(12):2400-2405.
22. de Wolf F.A., Maliepaard M., van Dorsten F., Berghuis I., Nicolay K., de Kruijff B. Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics. Biochim. Biophys. Acta 1991, 1096:67-80.
23. Nicolay K., Sautereau A., Tocanne J.F., Brasseur R., Huart P., Ruysschaert J.M., de Kruijff B. A comparative model membrane study on structural effects of membrane-active positively charged anti-tumor drugs. Biochim. Biophys. Acta 1988, 940:197-208.
24. Constantinides P.P., Inouchi N., Tritton T.R., Sartorelli A.C., Sturtevant J.M. A scanning calorimetric study of the interaction of anthracyclines with neutral and acidic phospholipids alone and in binary mixtures. J. Biol. Chem. 1986, 261(22):10196-10203.
25. McIntosh T.J., McDaniel R.V., Simon S.A. Induction of an interdigitated gel phase in fully hydrated lecithin bilayers. Biochim. Biophys. Acta 1983, 731:109-114.
26. Borden M.A., Longo M.L. Oxygen permeability of fully condensed lipid monolayers. J. Phys. Chem. B 2004, 108:6009-6016.
27. I. Lentacker, Design and Evaluation of Drug Loaded Microbubbles for Ultrasound Guided Cancer Therapy. Faculty of Pharmaceutical Sciences, Vol. Doctor in Pharmaceutical Sciences, Ghent University, Ghent, 2009, p. 216.
28. Kegel W.K., van der Schoot P. Competing hydrophobic and screened-Coulomb interactions in hepatitis B virus capsid assembly. Biophys. J. 2004, 86:3905-3913.
29. Greis C. Technology overview: Sonovue (Bracco, Milan). Eur. Radiol. Suppl. 2004, 14(Suppl 8):11-15.
30. Mhawi A.A., Fernandes A.B., Ottensmeyer F.P. Low-energy-loss electron microscopy of doxorubicin in human breast cancer MCF-7 cells: localization by color. J. Struct. Biol. 2007, 158(1):80-92.
31. Burke T., Tritton T.R. Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles: an equilibrium binding study. Biochemistry 1985, 24:1768-1776.